Randomized data from CMB305 + checkpoint inhibitor study show clinical benefit and immune response

Keytruda improves outcomes in soft tissue sarcoma

Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.

November 15, 2024

Vol.50 No.43

Clinical Roundup

UCLA investigators develop collection of sarcoma patient-derived organoids for personalized cancer treatments

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.

September 27, 2024

Vol.50 No.36

Clinical Roundup

Novel tumor models provide insights into deadly sarcomas

Investigators at UC Davis Comprehensive Cancer Center and UCLA Health’s Jonsson Comprehensive Cancer Center report they have manipulated mesenchymal stem cells to create four different sarcoma models.

September 20, 2024

Vol.50 No.35

Drugs & Targets

FDA grants Orphan Drug designation to elraglusib for soft tissue sarcomas

FDA has granted orphan drug designation for the GSK-3β inhibitor elraglusib, for treatment of soft tissue sarcoma.

September 13, 2024

Vol.50 No.34

Drugs & Targets

FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma

FDA has granted an accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.

August 02, 2024

Vol.50 No.31

Clinical Roundup

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas on April 24 in Nature Cancer.

April 26, 2024

Vol.50 No.17

Randomized data from CMB305 + checkpoint inhibitor study show clinical benefit and immune response

YOU MAY BE INTERESTED IN

Keytruda improves outcomes in soft tissue sarcoma

UCLA investigators develop collection of sarcoma patient-derived organoids for personalized cancer treatments

Novel tumor models provide insights into deadly sarcomas

FDA grants Orphan Drug designation to elraglusib for soft tissue sarcomas

FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Renew today!

Subscriber content

Never miss an issue!

Login